Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UNITED THERAPEUTICS (UTHR) EPS (Weighted Average and Diluted): 2009-2024

Historic EPS (Weighted Average and Diluted) for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to $24.64.

  • UNITED THERAPEUTICS's EPS (Weighted Average and Diluted) rose 12.05% to $7.16 in Q3 2025 from the same period last year, while for Sep 2025 it was $26.41, marking a year-over-year increase of 16.14%. This contributed to the annual value of $24.64 for FY2024, which is 24.38% up from last year.
  • UNITED THERAPEUTICS's EPS (Weighted Average and Diluted) amounted to $24.64 in FY2024, which was up 24.38% from $19.81 recorded in FY2023.
  • Over the past 5 years, UNITED THERAPEUTICS's EPS (Weighted Average and Diluted) peaked at $24.64 during FY2024, and registered a low of $10.06 during FY2021.
  • Its 3-year average for EPS (Weighted Average and Diluted) is $19.82, with a median of $19.81 in 2023.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first skyrocketed by 582.85% in 2020, then fell by 12.82% in 2021.
  • UNITED THERAPEUTICS's EPS (Weighted Average and Diluted) (Yearly) stood at $11.54 in 2020, then decreased by 12.82% to $10.06 in 2021, then skyrocketed by 49.11% to $15 in 2022, then spiked by 32.07% to $19.81 in 2023, then increased by 24.38% to $24.64 in 2024.